<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med Res</journal-id><journal-id journal-id-type="publisher-id">Elmer Press</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine Research</journal-title></journal-title-group><issn pub-type="ppub">1918-3003</issn><issn pub-type="epub">1918-3011</issn><publisher><publisher-name>Elmer Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28090225</article-id><article-id pub-id-type="pmc">5215013</article-id><article-id pub-id-type="doi">10.14740/jocmr2838w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Combination Therapy Consisting of Angiotensin II Type 1 Receptor Blocker, Calcium Channel Blocker and Hydrochlorothiazide in Patients With Hypertension</article-title><alt-title alt-title-type="short">Efficacy and Safety of Combination Therapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shiga</surname><given-names>Yuhei</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Miura</surname><given-names>Shin-ichiro</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="corresp" rid="CORf">f</xref></contrib><contrib contrib-type="author"><name><surname>Motozato</surname><given-names>Kota</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ad">d</xref></contrib><contrib contrib-type="author"><name><surname>Yoshimine</surname><given-names>Yuka</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Norimatsu</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Arimura</surname><given-names>Tadaaki</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Koyoshi</surname><given-names>Rie</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="aff" rid="Ae">e</xref></contrib><contrib contrib-type="author"><name><surname>Morii</surname><given-names>Joji</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Kuwano</surname><given-names>Takashi</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib><contrib contrib-type="author"><name><surname>Inoue</surname><given-names>Ken</given-names></name><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Shirotani</surname><given-names>Tetsuro</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Fujisawa</surname><given-names>Kazuaki</given-names></name><xref ref-type="aff" rid="Ad">d</xref></contrib><contrib contrib-type="author"><name><surname>Matsunaga</surname><given-names>Eiyu</given-names></name><xref ref-type="aff" rid="Ae">e</xref></contrib><contrib contrib-type="author"><name><surname>Saku</surname><given-names>Keijiro</given-names></name><xref ref-type="aff" rid="Aa">a</xref></contrib></contrib-group><aff id="Aa"><label>a</label>Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan</aff><aff id="Ab"><label>b</label>Inoue Hospital, Fukuoka, Japan</aff><aff id="Ac"><label>c</label>Shirotani Hospital, Fukuoka, Japan</aff><aff id="Ad"><label>d</label>Fujisawa Clinic, Fukuoka, Japan</aff><aff id="Ae"><label>e</label>Matsunaga Hospital, Fukuoka, Japan</aff><author-notes><corresp id="CORf"><label>f</label>Corresponding Author: Shin-ichiro Miura, Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. Email: <email>miuras@cis.fukuoka-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>2</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2016</year></pub-date><volume>9</volume><issue>2</issue><fpage>98</fpage><lpage>103</lpage><history><date date-type="accepted"><day>20</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright 2017, Shiga et al.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="a1"><title>Background</title><p>Many patients continue to have high blood pressure (BP) even after treatment with high-dose (H)-angiotensin II type 1 receptor blocker (ARB)/calcium channel blocker (CCB) or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ).</p></sec><sec id="a2"><title>Methods</title><p>Thirty-two hypertensive patients who had the use of H-ARB/CCB or M-ARB/CCB/HCTZ were enrolled in this study. We applied a changeover with a switch to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day).</p></sec><sec id="a3"><title>Results</title><p>Systolic BP (SBP) and diastolic BP (DBP) were significantly decreased in all patients and in the H-ARB/CCB and M-ARB/CCB/HCTZ groups after 3 months. Percentage (%) of patients who reached the target BP after 3 months (72%) in all patients was significantly higher than that at 0 months (19%). There were no serious adverse effects in any of the patients.</p></sec><sec id="a4"><title>Conclusions</title><p>Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Blood pressure</kwd><kwd>Calcium channel blocker</kwd><kwd>Angiotensin II type 1 receptor blocker</kwd><kwd>Hydrochlorothiazide</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Most patients with hypertension (HTN) require two or more drugs to achieve their target blood pressure (BP) [<xref rid="R01" ref-type="bibr">1</xref>]. In fact, large-scale clinical trials have shown that thiazide diuretics and/or calcium channel blockers (CCBs) are frequently needed in addition to angiotensin II type 1 receptor blockers (ARBs) to achieve adequate BP control [<xref rid="R02" ref-type="bibr">2</xref>]. Although various guidelines recommend the use of combinations of ARBs and CCBs or diuretics [<xref rid="R03" ref-type="bibr">3</xref>, <xref rid="R04" ref-type="bibr">4</xref>], we use three kinds of anti-hypertensive drugs when two drugs do not provide a significant reduction of BP. Although approximately 15% of patients receive three drugs, there have been few reports on whether combination therapy with three drugs is superior to a combination of two drugs [<xref rid="R05" ref-type="bibr">5</xref>]. Many patients continue to show a high BP even after treatment with high-dose (H) ARB/CCB or middle-dose (M)-ARB/CCB/hydrochlorothiazide (HCTZ), although optimal BP control is associated with remarkable clinical benefits with regard to cardiovascular and renal protection. Therefore, we analyzed whether a changeover with a switch from combination therapy with H-ARB/CCB or M-ARB/CCB/HCTZ to combination therapy with H-ARB/CCB/HTCZ can offer better efficacy and safety in patients with HTN.</p></sec><sec sec-type="materials | methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>Thirty-two hypertensive patients who had the use of H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day) or M-ARB (losartan 50 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day) more than 1 month (average 3.9 &#x000b1; 6.9 months) were enrolled. We applied a changeover with a switch from H-ARB/CCB (H-ARB/CCB group) or M-ARB/CCB/HCTZ (M-ARB/CCB/HCTZ group) to H-ARB (telmisartan 80 mg/day)/CCB (amlodipine 5 mg/day or nifedipine CR 40 mg/day)/HCTZ (12.5 mg/day). We did not change the kind or dose of CCB and analyzed various parameters at baseline (0 months) and after 3 months. We excluded patients with secondary HTN, heart failure of NYHA grade III or IV, liver dysfunction, renal dysfunction (defined as a serum creatinine (Cr) level of more than 2.0 mg/dL), pregnancy, or a history of allergy to ARB, CCB or HCTZ. The target BP followed the Japanese Society of Hypertension Guidelines for the Management of Hypertension 2009 (JSH2009) [<xref rid="R03" ref-type="bibr">3</xref>]. The protocol in this study was approved by the ethics committee of Fukuoka University Hospital, and all subjects gave their informed consent to participate.</p></sec><sec id="s2b"><title>Evaluation of clinical parameters</title><p>Office systolic BP (SBP), diastolic BP (DBP) and pulse rate (PR) measurements were obtained at 0, 1, 2 and 3 months. Body weight (BW), blood and urinary levels of biochemical parameters were obtained at 0 and 3 months. BP was determined as the mean of two measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 min of rest. All of the blood samples were collected in the morning after the patients had fasted overnight. Data regarding serum levels of biochemical parameters, such as high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), uric acid (UA), creatinine (Cr), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), sodium (Na) and potassium (K) were collected in all patients. Body mass index (BMI) was calculated as BW (kg)/height (m)<sup>2</sup>.</p><p>The characteristics of the patients with regard to history of dyslipidemia (DL), diabetes mellitus (DM), hyperuricemia (HU), smoking status and medication use were obtained from medical records. Patients with LDL-C &#x02265; 140 mg/dL, TG &#x02265; 150 mg/dL, and/or HDL-C &#x0003c; 40 mg/dL, or who were receiving lipid-lowering therapy, were considered to have DL. DM was defined using the Japanese Diabetes Association criteria or the use of a glucose-lowering drug. HU was defined as a serum UA level of &#x02265; 7.0 mg/dL or the use of uric acid-lowering drugs.</p></sec><sec id="s2c"><title>Statistical analysis</title><p>Statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) at Fukuoka University (Fukuoka, Japan). Data are presented as the mean &#x000b1; standard deviation (SD). Categorical and continuous variables were compared between the groups by a Chi-square analysis and unpaired <italic>t</italic>-test, respectively. Changes in SBP, DBP, PR, and clinical parameters following therapy were analyzed by the paired <italic>t</italic>-test. A value of P &#x0003c; 0.05 was considered significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patient characteristics in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups</title><p>
<xref ref-type="table" rid="T1">Table 1</xref> shows the characteristics of the 32 patients, who consisted of 16 (50 %) males. The prevalence of DL, DM and HU was 56%, 16% and 19%, respectively. There were no significant differences in these patient characteristics between the H-ARB/CCB and M-ARB/M-CCB/HTCZ groups. The percentage use of &#x003b2;-blocker and &#x003b1;-blocker was 3% and 3%, respectively (<xref ref-type="table" rid="T2">Table 2</xref>). There were no significant differences in medications between the groups. We did not change these medications throughout the study period.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Baseline Patient Characteristics in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All patients (n = 32)</th><th align="left" rowspan="1" colspan="1">H-ARB/CCB (n = 20)</th><th align="left" rowspan="1" colspan="1">M-ARB/CCB/HTCZ (n =12)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, years</td><td align="left" valign="top" rowspan="1" colspan="1">69 &#x000b1; 15</td><td align="left" valign="top" rowspan="1" colspan="1">69 &#x000b1; 16</td><td align="left" valign="top" rowspan="1" colspan="1">68 &#x000b1; 13</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gender (male), n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">16 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (55)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (42)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Smoking, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (34)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (40)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (25)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup></td><td align="left" valign="top" rowspan="1" colspan="1">23.9 &#x000b1; 4.3</td><td align="left" valign="top" rowspan="1" colspan="1">23.8 &#x000b1; 4.6</td><td align="left" valign="top" rowspan="1" colspan="1">24.0 &#x000b1; 3.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WC, cm</td><td align="left" valign="top" rowspan="1" colspan="1">85.7 &#x000b1; 10.2</td><td align="left" valign="top" rowspan="1" colspan="1">86.1 &#x000b1; 11.1</td><td align="left" valign="top" rowspan="1" colspan="1">87.0 &#x000b1; 8.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DL, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">18 (56)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (50)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (67)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;LDL-C, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">104 &#x000b1; 32</td><td align="left" valign="top" rowspan="1" colspan="1">106 &#x000b1; 35</td><td align="left" valign="top" rowspan="1" colspan="1">100 &#x000b1; 27</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;HDL-C, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">52 &#x000b1; 12</td><td align="left" valign="top" rowspan="1" colspan="1">51 &#x000b1; 13</td><td align="left" valign="top" rowspan="1" colspan="1">52 &#x000b1; 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TG, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">145 &#x000b1; 92</td><td align="left" valign="top" rowspan="1" colspan="1">138 &#x000b1; 92</td><td align="left" valign="top" rowspan="1" colspan="1">155 &#x000b1; 95</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DM, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">5 (16)</td><td align="left" valign="top" rowspan="1" colspan="1">3 (15)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (17)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Fasting glucose, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">102 &#x000b1; 29</td><td align="left" valign="top" rowspan="1" colspan="1">102 &#x000b1; 35</td><td align="left" valign="top" rowspan="1" colspan="1">103 &#x000b1; 16</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;HbA1c, %</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 &#x000b1; 0.9</td><td align="left" valign="top" rowspan="1" colspan="1">5.4 &#x000b1; 1.0</td><td align="left" valign="top" rowspan="1" colspan="1">5.2 &#x000b1; 0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HU, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (12)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;UA, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">5.4 &#x000b1; 1.3</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 &#x000b1; 1.2</td><td align="left" valign="top" rowspan="1" colspan="1">5.7 &#x000b1; 1.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CAD, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (13)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (20)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are expressed as mean &#x000b1; SD. BMI: body mass index; WC: waist circumference; DL: dyslipidemia; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; DM: diabetes mellitus; HbA1c: hemoglobin A1c; HU: hyperuricemia; UA: uric acid; CAD: coronary artery disease.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Medications in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">All patients (n = 32)</th><th align="left" rowspan="1" colspan="1">H-ARB/CCB (n = 20)</th><th align="left" rowspan="1" colspan="1">M-ARB/CCB/HTCZ (n = 12)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication use</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CCBs</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Nifedipine 40 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">25 (78)</td><td align="left" valign="top" rowspan="1" colspan="1">14 (70)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (92)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Amlodipine 5 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">7 (22)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x003b2;-blocker, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x003b1;-blocker, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (5)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Medication use before changeover</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;ARBs, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (63)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (100)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Telmisartan 80 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (38)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (60)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Olmesartan 40 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19)</td><td align="left" valign="top" rowspan="1" colspan="1">6 (30)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;Valsartan 160 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (6)</td><td align="left" valign="top" rowspan="1" colspan="1">2 (10)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Losartan 50 mg + HCTZ 12.5 mg, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (38)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (100)</td></tr></tbody></table><table-wrap-foot><fn><p>CCBs: calcium channel blockers; ARBs: angiotensin II receptor blockers; HCTZ: hydrochlorothiazide.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Time courses of BP and PR in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups</title><p>The time courses of BP and PR are shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. In all patients, significant reductions in SBP (142 &#x000b1; 12 to 125 &#x000b1; 15 mm Hg) and DBP (77 &#x000b1; 13 to 69 &#x000b1; 11 mm Hg), but not PR, were observed after 3 months. In the H-ARB/CCB group, SBP and DBP after 3 months were significantly lower than those at 0 months (SBP: 144 &#x000b1; 12 to 124 &#x000b1; 15 mm Hg, DBP: 76 &#x000b1; 10 to 67 &#x000b1; 10 mm Hg). In the M-ARB/CCB/HTCZ group, SBP after 3 months was significantly lower than that at 0 months (SBP: 139 &#x000b1; 12 to 127 &#x000b1; 15 mm Hg).</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Changes in SBP, DBP and PR in all patients (n = 32) and in the H-ARB/CCB (n = 20) and M-ARB/CCB/HCTZ (n = 12) groups. *P &#x0003c; 0.05 vs. 0 months (M). </p></caption><graphic xlink:href="jocmr-09-098-g001"/></fig></sec><sec id="s3c"><title>Percentages (%) of patients who reached the target BP at 0 and 3 months in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups</title><p>The % patients who reached the target BP at 3 months in all patients (72%) and in H-ARB/CCB group (80 %) was significantly higher than that at 0 months (all patients (19%) and H-ARB/CCB group (15%) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). In addition, % patients who reached the target BP at 3 months (58%) tended to be higher than that at 0 months (25%) in the M-ARB/CCB (P &#x0003c; 0.10).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Percentages (%) of patients who reached the target BP at 0 and 3 months in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups. *P &#x0003c; 0.05 vs. 0 months. </p></caption><graphic xlink:href="jocmr-09-098-g002"/></fig></sec><sec id="s3d"><title>&#x00394;SBP and &#x00394;DBP in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups</title><p>Changes in SBP and DBP from 0 to 3 months (&#x00394; = the value at 3 months minus the value at 0 months) are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>. There were no significant differences in &#x00394;SBP or &#x00394;DBP among all patients or the H-ARB/CCB and M-ARB/CCB/HTCZ groups.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>&#x00394;SBP and &#x00394;DBP in all patients (n = 32) and in the H-ARB/CCB (n = 20) and M-ARB/CCB/HCTZ (n = 12) groups over 3 months. &#x00394; indicates the value at 3 months minus the value at 0 months. NS: not significant. </p></caption><graphic xlink:href="jocmr-09-098-g003"/></fig></sec><sec id="s3e"><title>Changes in biochemical parameters in all patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ groups</title><p>As shown in <xref ref-type="table" rid="T3">Table 3</xref>, there were no significant changes in biochemical parameters including Cr, BNP and the lipid profile in all patients or the H-ARB/CCB and M-ARB/CCB/HTCZ groups. On the other hand, all patients and the H-ARB/CCB group showed significantly increased serum UA, and all patients showed significantly increased serum HbA1c.</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Biochemical Parameters at 0 and 3 Months in All Patients and in the H-ARB/CCB and M-ARB/CCB/HTCZ Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">All patients (n = 32)<hr/></th><th align="center" colspan="2" rowspan="1">H-ARB/CCB (n = 20)<hr/></th><th align="center" colspan="2" rowspan="1">M-ARB/CCB/HTCZ (n = 12)<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">0 months</th><th align="left" rowspan="1" colspan="1">3 months</th><th align="left" rowspan="1" colspan="1">0 months</th><th align="left" rowspan="1" colspan="1">3 months</th><th align="left" rowspan="1" colspan="1">0 months</th><th align="left" rowspan="1" colspan="1">3 months</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">BUN, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">18 &#x000b1; 11</td><td align="left" valign="top" rowspan="1" colspan="1">20 &#x000b1; 12</td><td align="left" valign="top" rowspan="1" colspan="1">17 &#x000b1; 12</td><td align="left" valign="top" rowspan="1" colspan="1">21 &#x000b1; 15</td><td align="left" valign="top" rowspan="1" colspan="1">20 &#x000b1; 7</td><td align="left" valign="top" rowspan="1" colspan="1">19 &#x000b1; 6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cr, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 &#x000b1; 0.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.5</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 &#x000b1; 0.4</td><td align="left" valign="top" rowspan="1" colspan="1">1.0 &#x000b1; 0.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.9 &#x000b1; 0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">eGFR, mL/min/1.73 m<sup>2</sup></td><td align="left" valign="top" rowspan="1" colspan="1">63 &#x000b1; 21</td><td align="left" valign="top" rowspan="1" colspan="1">61 &#x000b1; 23</td><td align="left" valign="top" rowspan="1" colspan="1">67 &#x000b1; 22</td><td align="left" valign="top" rowspan="1" colspan="1">63 &#x000b1; 25</td><td align="left" valign="top" rowspan="1" colspan="1">56 &#x000b1; 18</td><td align="left" valign="top" rowspan="1" colspan="1">60 &#x000b1; 20</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UA, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">5.4 &#x000b1; 1.3</td><td align="left" valign="top" rowspan="1" colspan="1">6.0 &#x000b1; 1.3*</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 &#x000b1; 1.2</td><td align="left" valign="top" rowspan="1" colspan="1">6.0 &#x000b1; 1.3*</td><td align="left" valign="top" rowspan="1" colspan="1">5.7 &#x000b1; 1.4</td><td align="left" valign="top" rowspan="1" colspan="1">6.2 &#x000b1; 1.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Na, mEq/L</td><td align="left" valign="top" rowspan="1" colspan="1">141 &#x000b1; 2</td><td align="left" valign="top" rowspan="1" colspan="1">140 &#x000b1; 3</td><td align="left" valign="top" rowspan="1" colspan="1">141 &#x000b1; 2</td><td align="left" valign="top" rowspan="1" colspan="1">140 &#x000b1; 3</td><td align="left" valign="top" rowspan="1" colspan="1">140 &#x000b1; 2</td><td align="left" valign="top" rowspan="1" colspan="1">140 &#x000b1; 3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">K, mEq/L</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 &#x000b1; 0.5</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 &#x000b1; 0.7</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 &#x000b1; 0.6</td><td align="left" valign="top" rowspan="1" colspan="1">4.2 &#x000b1; 0.7</td><td align="left" valign="top" rowspan="1" colspan="1">4.0 &#x000b1; 0.4</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 &#x000b1; 0.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TG, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">145 &#x000b1; 92</td><td align="left" valign="top" rowspan="1" colspan="1">135 &#x000b1; 72</td><td align="left" valign="top" rowspan="1" colspan="1">138 &#x000b1; 92</td><td align="left" valign="top" rowspan="1" colspan="1">120 &#x000b1; 61</td><td align="left" valign="top" rowspan="1" colspan="1">155 &#x000b1; 95</td><td align="left" valign="top" rowspan="1" colspan="1">159 &#x000b1; 84</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LDL-C, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">104 &#x000b1; 32</td><td align="left" valign="top" rowspan="1" colspan="1">102 &#x000b1; 30</td><td align="left" valign="top" rowspan="1" colspan="1">106 &#x000b1; 35</td><td align="left" valign="top" rowspan="1" colspan="1">104 &#x000b1; 34</td><td align="left" valign="top" rowspan="1" colspan="1">127 &#x000b1; 46</td><td align="left" valign="top" rowspan="1" colspan="1">129 &#x000b1; 31</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HDL-C, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">52 &#x000b1; 12</td><td align="left" valign="top" rowspan="1" colspan="1">56 &#x000b1; 16</td><td align="left" valign="top" rowspan="1" colspan="1">51 &#x000b1; 13</td><td align="left" valign="top" rowspan="1" colspan="1">58 &#x000b1; 18</td><td align="left" valign="top" rowspan="1" colspan="1">52 &#x000b1; 10</td><td align="left" valign="top" rowspan="1" colspan="1">52 &#x000b1; 10</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FPG, mg/dL</td><td align="left" valign="top" rowspan="1" colspan="1">102 &#x000b1; 229</td><td align="left" valign="top" rowspan="1" colspan="1">116 &#x000b1; 81</td><td align="left" valign="top" rowspan="1" colspan="1">102 &#x000b1; 35</td><td align="left" valign="top" rowspan="1" colspan="1">122 &#x000b1; 10</td><td align="left" valign="top" rowspan="1" colspan="1">103 &#x000b1; 16</td><td align="left" valign="top" rowspan="1" colspan="1">106 &#x000b1; 24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HbA1c, %</td><td align="left" valign="top" rowspan="1" colspan="1">5.3 &#x000b1; 0.9</td><td align="left" valign="top" rowspan="1" colspan="1">5.5 &#x000b1; 0.8*</td><td align="left" valign="top" rowspan="1" colspan="1">5.4 &#x000b1; 1.0</td><td align="left" valign="top" rowspan="1" colspan="1">5.5 &#x000b1; 1.0</td><td align="left" valign="top" rowspan="1" colspan="1">5.2 &#x000b1; 0.5</td><td align="left" valign="top" rowspan="1" colspan="1">5.4 &#x000b1; 0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BNP, pg/mL</td><td align="left" valign="top" rowspan="1" colspan="1">67 &#x000b1; 92</td><td align="left" valign="top" rowspan="1" colspan="1">55 &#x000b1; 72</td><td align="left" valign="top" rowspan="1" colspan="1">66 &#x000b1; 70</td><td align="left" valign="top" rowspan="1" colspan="1">66 &#x000b1; 87</td><td align="left" valign="top" rowspan="1" colspan="1">70 &#x000b1; 124</td><td align="left" valign="top" rowspan="1" colspan="1">36 &#x000b1; 28</td></tr></tbody></table><table-wrap-foot><fn><p>BUN: blood urea nitrogen; Cr: creatinine; eGFR: estimated glomerular filtration rate; UA: uric acid; Na: sodium; K: potassium; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FPG: fast plasma glucose; HbA1c: hemoglobin A1c; BNP: brain natriuretic peptide. *P &#x0003c; 0.05 vs. 0 months.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>In the present study, combination therapy with H-ARB/CCB/HTCZ induced a significant reduction of BP after patients switched from H-ARB/CCB or M-ARB/CCB/HTCZ. BP control is the best strategy for achieving remarkable clinical benefits with regard to cardiovascular and renal protection. There are two main explanations for why H-ARB/CCB/HTCZ induced a significant reduction in BP. First, 12.5 mg/day of HCTZ significantly increased plasma renin activity (PRA) [<xref rid="R06" ref-type="bibr">6</xref>]. In this study, the blockade of PRA activation by HTCZ using H-ARB (telmisartan 80 mg/day) may be stronger than that using M-ARB (losartan 50 mg/day). Second, telmisartan 80 mg/day itself had significantly greater depressor effects than losartan 50 mg/day [<xref rid="R07" ref-type="bibr">7</xref>].</p><p>In this study, combination therapy with H-ARB/CCB/HTCZ significantly increased serum UA after patients were switched from H-ARB/CCB because of the addition of HTCZ. Telmisartan in Micombi<sup>&#x000ae;</sup>BP partially activates peroxisome proliferator-activated receptor-&#x003b3; [<xref rid="R08" ref-type="bibr">8</xref>], which may improve insulin sensitivity. This effect may be useful in hypertensive patients with insulin resistance or DM [<xref rid="R09" ref-type="bibr">9</xref>]. Unexpectedly, although H-ARB (telmisartan 80 mg/day)/CCB/HTCZ significantly increased serum HbA1c levels in all patients, there were no serious adverse effects in any of the patients.</p><sec id="s4a"><title>Study limitations</title><p>This study has three important limitations. First, the sample size was relatively small, which limits our ability to determine significance. Second, we applied a changeover with switching from H-ARB/CCB or M-ARB/CCB/HCTZ. A crossover study would have been preferable. Third, we measured BP and PR for only 3 months and did not evaluate the clinical outcome. Long-term prospective studies are needed to clarify the limitation.</p></sec><sec id="s4b"><title>Conclusions</title><p>Combination therapy with H-ARB/CCB/HCTZ was associated with a significant reduction of BP. Although serum UA and HbA1c increased after 3 months, there were no serious adverse effects in any of the patients.</p></sec></sec></body><back><sec id="s5"><title>Conflicts of Interest</title><p>KS is a Chief Director and SM is a Director of NPO Clinical and Applied Science, Fukuoka, Japan. KS has an Endowed &#x0201c;Department of Molecular Cardiovascular Therapeutics&#x0201d; supported by MSD, Co. Ltd. SM belongs to the Department of Molecular Cardiovascular Therapeutics, which is supported by MSD, Co. Ltd.</p></sec><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>Dahlof</surname><given-names>B</given-names></name><name><surname>Sever</surname><given-names>PS</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Beevers</surname><given-names>DG</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>R</given-names></name><etal>et al</etal><article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9489</issue><fpage>895</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67185-1</pub-id><pub-id pub-id-type="pmid">16154016</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Kato</surname><given-names>J</given-names></name><name><surname>Eto</surname><given-names>T</given-names></name><article-title>Diuretics in the LIFE study</article-title><source>Lancet</source><year>2004</year><volume>364</volume><issue>9432</issue><fpage>413</fpage><comment>author reply 413-414</comment><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16755-X</pub-id><pub-id pub-id-type="pmid">15288732</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Matsuoka</surname><given-names>H</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Horiuchi</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><etal>et al</etal><article-title>The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)</article-title><source>Hypertens Res</source><year>2009</year><volume>32</volume><issue>1</issue><fpage>3</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/hr.2009.34</pub-id><pub-id pub-id-type="pmid">19300436</pub-id></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><etal>et al</etal><article-title>2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><issue>6</issue><fpage>1105</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3281fc975a</pub-id><pub-id pub-id-type="pmid">17563527</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Okubo</surname><given-names>S</given-names></name><name><surname>Toi</surname><given-names>T</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Tada</surname><given-names>J</given-names></name><etal>et al</etal><article-title>The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial</article-title><source>Hypertens Res</source><year>2010</year><volume>33</volume><issue>12</issue><fpage>1264</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1038/hr.2010.175</pub-id><pub-id pub-id-type="pmid">20927115</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Villamil</surname><given-names>A</given-names></name><name><surname>Chrysant</surname><given-names>SG</given-names></name><name><surname>Calhoun</surname><given-names>D</given-names></name><name><surname>Schober</surname><given-names>B</given-names></name><name><surname>Hsu</surname><given-names>H</given-names></name><name><surname>Matrisciano-Dimichino</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><article-title>Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><issue>1</issue><fpage>217</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e3280103a6b</pub-id><pub-id pub-id-type="pmid">17143194</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><name><surname>Bakris</surname><given-names>G</given-names></name><name><surname>Burgess</surname><given-names>E</given-names></name><name><surname>Weir</surname><given-names>M</given-names></name><name><surname>Davidai</surname><given-names>G</given-names></name><name><surname>Koval</surname><given-names>S</given-names></name><article-title>Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy</article-title><source>Kidney Int</source><year>2008</year><volume>74</volume><issue>3</issue><fpage>364</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/ki.2008.204</pub-id><pub-id pub-id-type="pmid">18496508</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Benson</surname><given-names>SC</given-names></name><name><surname>Pershadsingh</surname><given-names>HA</given-names></name><name><surname>Ho</surname><given-names>CI</given-names></name><name><surname>Chittiboyina</surname><given-names>A</given-names></name><name><surname>Desai</surname><given-names>P</given-names></name><name><surname>Pravenec</surname><given-names>M</given-names></name><name><surname>Qi</surname><given-names>N</given-names></name><etal>et al</etal><article-title>Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity</article-title><source>Hypertension</source><year>2004</year><volume>43</volume><issue>5</issue><fpage>993</fpage><lpage>1002</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000123072.34629.57</pub-id><pub-id pub-id-type="pmid">15007034</pub-id></element-citation></ref><ref id="R09"><label>9</label><element-citation publication-type="journal"><name><surname>Suksomboon</surname><given-names>N</given-names></name><name><surname>Poolsup</surname><given-names>N</given-names></name><name><surname>Prasit</surname><given-names>T</given-names></name><article-title>Systematic review of the effect of telmisartan on insulin sensitivity in hypertensive patients with insulin resistance or diabetes</article-title><source>J Clin Pharm Ther</source><year>2012</year><volume>37</volume><issue>3</issue><fpage>319</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2710.2011.01295.x</pub-id><pub-id pub-id-type="pmid">21848583</pub-id></element-citation></ref></ref-list></back></article>